MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Regeneron Pharmaceuticals Inc

Suletud

SektorTervishoid

616.89 -2.65

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

614.25

Max

640.1

Põhinäitajad

By Trading Economics

Sissetulek

-423M

918M

Müük

69M

3.8B

P/E

Sektori keskmine

16.529

63.778

Aktsiakasum

12.07

Dividenditootlus

0.56

Kasumimarginaal

24.219

Töötajad

15,106

EBITDA

-534M

1.1B

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+54.17% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.56%

2.39%

Järgmine tulemuste avaldamine

29. apr 2025

Turustatistika

By TradingEconomics

Turukapital

-5B

70B

Eelmine avamishind

619.54

Eelmine sulgemishind

616.89

Uudiste sentiment

By Acuity

41%

59%

143 / 386 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

Regeneron Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

4. veebr 2025, 12:13 UTC

Tulu

Regeneron 4Q Revenue Up on Strong Sales of EYLEA HD

8. juuli 2024, 12:00 UTC

Tulu

Regeneron Expects Earnings Hit After $24 Million R&D Charge

28. veebr 2025, 12:00 UTC

Peamised uudised

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

4. veebr 2025, 11:58 UTC

Tulu

Regeneron 4Q Rev Up on Strong Sales of EYLEA HD

4. veebr 2025, 11:37 UTC

Tulu

Regeneron Pharma Sees 2025 Adjusted R&D $5B-$5.2B >REGN

4. veebr 2025, 11:37 UTC

Tulu

Regeneron Pharma Sees 2025 Gross Margin on Net Product Sales 87%-88% >REGN

4. veebr 2025, 11:36 UTC

Tulu

Regeneron Pharma Sees 2025 Capital Spending $850M-$975M >REGN

4. veebr 2025, 11:35 UTC

Tulu

Regeneron Pharma Declares Initial Quarterly Dividend of 88c >REGN

4. veebr 2025, 11:35 UTC

Tulu

Regeneron Pharma 4Q Adj EPS $12.07 >REGN

4. veebr 2025, 11:34 UTC

Tulu

Regeneron Pharma 4Q U.S. Net Sales for Eylea HD, Eylea Rose 2% to $1.5B >REGN

4. veebr 2025, 11:34 UTC

Tulu

Regeneron Pharma: 4Q Dupixent Global Net Sales Recorded by Sanofi Rose 15% to $3.7B >REGN

4. veebr 2025, 11:32 UTC

Tulu

Regeneron Pharma Board OKs Additional $3 Billion Share Repurchase >REGN

4. veebr 2025, 11:31 UTC

Tulu

Regeneron Pharma Initiates Quarterly Cash Dividend Program >REGN

31. jaan 2025, 08:30 UTC

Omandamised, ülevõtmised, äriostud

It's Bananas, but Stock Splits Can Pay Off. Here Are 5 Likely Contenders. -- Barrons.com

28. jaan 2025, 10:30 UTC

Peamised uudised

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

31. okt 2024, 13:58 UTC

Tulu

Regeneron Takes A Ghastly Turn As High-Dose Eylea Lags And Biosimilars Loom -- IBD

31. okt 2024, 10:52 UTC

Tulu

Regeneron Earnings Top Views For Biotech Giant -- IBD

31. okt 2024, 10:34 UTC

Tulu

Regeneron Pharma 3Q Adj EPS $12.46 >REGN

31. okt 2024, 10:33 UTC

Tulu

Regeneron Pharma 3Q EPS Cut 43c by Acquired IPR&D Charge >REGN

31. okt 2024, 10:33 UTC

Tulu

Regeneron Pharma 3Q U.S. Sales for Eylea HD, Eylea Rose 3% to $1.54B >REGN

31. okt 2024, 10:32 UTC

Tulu

Regeneron Pharma: 3Q Dupixent Global Net Sales Recorded by Sanofi Rose 23% to $3.82B >REGN

31. okt 2024, 10:30 UTC

Tulu

Regeneron Pharma 3Q Rev $3.72B >REGN

31. okt 2024, 10:30 UTC

Tulu

Regeneron Pharma 3Q EPS $11.54 >REGN

31. okt 2024, 10:30 UTC

Tulu

Regeneron Pharma 3Q Net $1.34B >REGN

25. okt 2024, 20:25 UTC

Tulu

Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat -- IBD

1. aug 2024, 11:50 UTC

Tulu

Regeneron Stock Climbs After Strong Second-Quarter Performance -- IBD

1. aug 2024, 10:37 UTC

Tulu

Regeneron Pharma 2Q Adj EPS $11.56 >REGN

1. aug 2024, 10:30 UTC

Tulu

Regeneron Pharma 2Q EPS $12.41 >REGN

1. aug 2024, 10:30 UTC

Tulu

Regeneron Pharma 2Q Net $1.43B >REGN

1. aug 2024, 10:30 UTC

Tulu

Regeneron Pharma 2Q Rev $3.55B >REGN

Võrdlus sarnastega

Hinnamuutus

Regeneron Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

54.17% tõus

12 kuu keskmine prognoos

Keskmine 951.25 USD  54.17%

Kõrge 1,182 USD

Madal 575 USD

Põhineb 20 Wall Streeti analüütiku instrumendi Regeneron Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

20 ratings

16

Osta

3

Hoia

1

Müü

Tehniline skoor

By Trading Central

629.02 / 662.33Toetus ja vastupanu

Lühikene perspektiiv

Bearish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

143 / 386 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.